<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989621</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-144</org_study_id>
    <nct_id>NCT04989621</nct_id>
  </id_info>
  <brief_title>Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)</brief_title>
  <official_title>Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) ï¼ša Single Arm, Open Label, Multi-center Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 trial studies the efficacy and safety of orelabrutinib plus rituximab followed&#xD;
      by maintenance with orelabrutinib for relapsed and refractory follicular lymphoma(RR FL)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>2 years</time_frame>
    <description>Complete remission rate will be determined on the basis of investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>4 years</time_frame>
    <description>The time from the start of treatment to the progression of the tumor or death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years</time_frame>
    <description>The time from the start of treatment to time of death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>4 years</time_frame>
    <description>The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>4 years</time_frame>
    <description>Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Relapsed and Refractory Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Orelabrutinib plus Rituximab followed by Maintenance with Orelabrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy: Patients receive Orelabrutinib at a dose of 25 mg once daily on days 1-28 and rituximab at a dose of 375mg/m2 on day 1. Treatment cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
If patients achieve CR or PR or SD, they will be treated with maintenance therapy Maintenance therapy: Patients receive Orelabrutinib every day at a dose of 150mg for up to two years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib and Rituximab</intervention_name>
    <description>Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.</description>
    <arm_group_label>Orelabrutinib plus Rituximab followed by Maintenance with Orelabrutinib</arm_group_label>
    <other_name>induction treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib</intervention_name>
    <description>Orelabrutinib 150mg po qd</description>
    <arm_group_label>Orelabrutinib plus Rituximab followed by Maintenance with Orelabrutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed grade 1, 2, or 3A FL;&#xD;
&#xD;
          -  Patients received prior anti-lymphoma treatment;&#xD;
&#xD;
          -  At least one evaluable lesion according to 2014 Lugano criteria;&#xD;
&#xD;
          -  Age 18 years or older;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) of 0-2;&#xD;
&#xD;
          -  Life expectancy &gt; 3 months;&#xD;
&#xD;
          -  Able to participate in all required study procedures;&#xD;
&#xD;
          -  Proper functioning of the major organs:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who required warfarin or had a history of stroke or intracranial hemorrhage&#xD;
             within 6 months, active transformed disease;&#xD;
&#xD;
          -  Histological transformation of follicular lymphoma;&#xD;
&#xD;
          -  Known central nervous system lymphoma;&#xD;
&#xD;
          -  Received a prior allogeneic hematopoietic stem cell transplant. Prior autologous&#xD;
             hematopoietic stem cell transplant is allowed;&#xD;
&#xD;
          -  Subjects who have received prior treatment with ibrutinib, or other BTK inhibitors;&#xD;
&#xD;
          -  Uncontrolled active infection, with the exception of tumor-related B symptom fever;&#xD;
&#xD;
          -  Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer&#xD;
             antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation&#xD;
             therapy or other investigational agents within 3 weeks, or major surgery within 4&#xD;
             weeks of first dose of study drug;&#xD;
&#xD;
          -  Subjects who progressed or become refractory while on treatment with PI3K inhibitors&#xD;
             are excluded. However, subjects who were responding to PI3K inhibitors, but had&#xD;
             treatment discontinued due to toxicity, are eligible;&#xD;
&#xD;
          -  Patients require treatment with strong CYP3A inhibitors;&#xD;
&#xD;
          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             Screening;&#xD;
&#xD;
          -  Patients with active hepatitis B or active hepatitis C. Patients who are positive for&#xD;
             hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening&#xD;
             stage must pass further detection of hepatitis B Virus (HBV) DNA (no more than 1000&#xD;
             IU/mL) and HCV RNA (no more than the lower limit of the detection method) in the row.&#xD;
             Hepatitis B carriers, stable hepatitis B (DNA titer should not be higher than 1000&#xD;
             IU/mL) after drug treatment, and cured hepatitis C patients can be enrolled in the&#xD;
             group;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingqing Cai</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingqing Cai</last_name>
    <phone>0086-20-87342823</phone>
    <email>caiqq@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenyu Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yudan Wu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qing qing Cai, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Qingqing Cai</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

